Ms. Samira Sakhia reports

NOTICE OF KNIGHT THERAPEUTICS' SECOND QUARTER 2023 RESULTS CONFERENCE CALL

Knight Therapeutics Inc. will release its second quarter 2023 financial results on Thursday, Aug. 10, 2023, prior to market opening. Following the release, Knight Therapeutics will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call.

Date:  Thursday, Aug. 10, 2023

Time:  8:30 a.m. ET

Telephone:  toll-free: 1-888-664-6383 or international: 1-416-764-8650

Webcast:  at the Knight Therapeutics website; this is a listen-only audio webcast; Media Player is required to listen to the broadcast

Replay:  An archived replay will be available for 30 days at the company's website.

About Knight Therapeutics Inc.

Knight Therapeutics, headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight Therapeutics' Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics' shares trade on the Toronto Stock Exchange under the symbol GUD.

We seek Safe Harbor.